Aligos Therapeutics, Inc. (ALGS)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 741K | 169K | 2.8M | 27.8M |
| Operating Income | (28.4M) | (21.8M) | (26.9M) | (1.9M) |
| Net Income | (31.5M) | (19.9M) | (23.0M) | (1.5M) |
| Diluted EPS | $-3.04 | $-1.91 | $-2.21 | $-0.14 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 13.9M | 15.5M | 3.9M | 2.2M |
| Operating Income | (97.6M) | (88.1M) | (89.2M) | (88.0M) |
| Net Income | (96.0M) | (87.7M) | (131.2M) | (24.2M) |
| Diluted EPS | $-56.25 | $-34.20 | $-20.94 | $-2.45 |